Savara Inc.

DB:YB4P Stock Report

Market Cap: €531.4m

Savara Valuation

Is YB4P undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of YB4P when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: YB4P (€3.08) is trading below our estimate of fair value (€3.96)

Significantly Below Fair Value: YB4P is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YB4P?

Key metric: As YB4P is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for YB4P. This is calculated by dividing YB4P's market cap by their current book value.
What is YB4P's PB Ratio?
PB Ratio2.8x
BookUS$199.35m
Market CapUS$556.05m

Price to Book Ratio vs Peers

How does YB4P's PB Ratio compare to its peers?

The above table shows the PB ratio for YB4P vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.8x
VSC 4SC
44.8xn/a€55.6m
FYB Formycon
1.4x31.5%€821.0m
BIO3 Biotest
2.1x82.7%€1.4b
HPHA Heidelberg Pharma
2.8x-33.0%€101.1m
YB4P Savara
2.8x52.5%€556.0m

Price-To-Book vs Peers: YB4P is good value based on its Price-To-Book Ratio (2.8x) compared to the peer average (12.8x).

Price to Book Ratio vs Industry

How does YB4P's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
YB4P 2.8xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: YB4P is expensive based on its Price-To-Book Ratio (2.8x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is YB4P's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YB4P PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.8x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate YB4P's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst YB4P forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.08
€9.34
+203.1%
39.8%€15.26€4.77n/a7
Nov ’25€3.26
€9.69
+197.1%
29.1%€14.37€6.29n/a7
Oct ’25€3.74
€9.69
+159.0%
29.1%€14.37€6.29n/a7
Sep ’25€3.84
€9.79
+155.0%
29.1%€14.52€6.35n/a7
Aug ’25€4.24
€10.01
+136.1%
30.6%€14.95€6.54n/a7
Jul ’25€3.82
€10.01
+162.1%
30.6%€14.95€6.54n/a7
Jun ’25€3.84
€8.29
+115.9%
35.6%€14.74€5.53n/a7
May ’25€4.28
€8.19
+91.4%
35.5%€14.92€5.59n/a7
Apr ’25€4.38
€8.03
+83.4%
35.5%€14.63€5.49n/a7
Mar ’25€4.74
€6.57
+38.5%
18.7%€8.82€4.64n/a7
Feb ’25€4.62
€5.92
+28.2%
11.4%€6.46€4.62n/a6
Jan ’25€4.32
€5.38
+24.6%
24.5%€6.55€2.81n/a6
Dec ’24€3.50
€5.38
+53.8%
24.5%€6.55€2.81n/a6
Nov ’24€3.38
€5.04
+49.2%
25.7%€6.42€2.75€3.265
Oct ’24€3.56
€5.04
+41.6%
25.7%€6.42€2.75€3.745
Sep ’24€3.54
€5.04
+42.4%
25.7%€6.42€2.75€3.845
Aug ’24€3.22
€4.70
+46.0%
32.6%€6.42€2.75€4.244
Jul ’24€2.90
€4.70
+62.1%
32.6%€6.42€2.75€3.824
Jun ’24€2.70
€4.64
+72.0%
31.6%€6.50€2.79€3.844
May ’24€1.69
€3.65
+116.0%
44.7%€6.39€1.83€4.285
Apr ’24€1.76
€3.86
+118.9%
44.7%€6.76€1.93€4.385
Mar ’24€2.30
€3.86
+67.7%
44.7%€6.76€1.93€4.745
Feb ’24€2.28
€3.86
+69.6%
44.7%€6.76€1.93€4.625
Jan ’24€1.40
€3.86
+176.2%
44.7%€6.76€1.93€4.325
Dec ’23€1.50
€3.86
+158.1%
44.7%€6.76€1.93€3.505
Nov ’23€1.24
€3.90
+213.8%
44.7%€6.82€1.95€3.385

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$705.00

7D

-7.1%

1Y

-3.8%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-6.2%

1Y

90.0%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$28.60

7D

0.7%

1Y

20.2%